Show simple item record

dc.contributor.authorKuhlin, J*
dc.contributor.authorSmith, C*
dc.contributor.authorKhaemraev, A*
dc.contributor.authorTigay, Z*
dc.contributor.authorParpieva, N*
dc.contributor.authorTillyashaykhov, M*
dc.contributor.authorAchar, J*
dc.contributor.authorHajek, J*
dc.contributor.authorGreig, J*
dc.contributor.authordu Cros, P*
dc.contributor.authorMoore, D*
dc.date.accessioned2018-05-08T14:25:41Z
dc.date.available2018-05-08T14:25:41Z
dc.date.issued2018-05-01
dc.date.submitted2018-04-30
dc.identifier.citationImpact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan. 2018, 22 (5):544-550 Int. J. Tuberc. Lung Dis.en
dc.identifier.issn1815-7920
dc.identifier.pmid29663960
dc.identifier.doi10.5588/ijtld.17.0483
dc.identifier.urihttp://hdl.handle.net/10144/619120
dc.description.abstractThe World Health Organization (WHO) recommends the inclusion of pyrazinamide (PZA) in treatment regimens for multidrug-resistant tuberculosis (MDR-TB) unless resistance has been confirmed.
dc.language.isoenen
dc.publisherInternational Union Against Tuberculosis and Lung Diseaseen
dc.rightsArchived with thanks to The International Journal of Tuberculosis and Lung Disease: the official journal of the International Union against Tuberculosis and Lung Diseaseen
dc.titleImpact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistanen
dc.identifier.journalThe International Journal of Tuberculosis and Lung Diseaseen
refterms.dateFOA2019-03-04T13:53:00Z
html.description.abstractThe World Health Organization (WHO) recommends the inclusion of pyrazinamide (PZA) in treatment regimens for multidrug-resistant tuberculosis (MDR-TB) unless resistance has been confirmed.


Files in this item

Thumbnail
Name:
Kuhlin et al - 2018 - Impact of ...
Size:
311.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record